Hanmi Pharm Co Ltd - Asset Resilience Ratio
Hanmi Pharm Co Ltd (128940) has an Asset Resilience Ratio of 6.91% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Hanmi Pharm Co Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2024)
This chart shows how Hanmi Pharm Co Ltd's Asset Resilience Ratio has changed over time. See net asset quality index of Hanmi Pharm Co Ltd to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Hanmi Pharm Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Hanmi Pharm Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩140.92 Billion | 6.91% |
| Total Liquid Assets | ₩140.92 Billion | 6.91% |
Asset Resilience Insights
- Limited Liquidity: Hanmi Pharm Co Ltd maintains only 6.91% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hanmi Pharm Co Ltd Industry Peers by Asset Resilience Ratio
Compare Hanmi Pharm Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Bausch Health Companies Inc
TO:BHC |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.15% |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Hainan Haiyao Co Ltd
SHE:000566 |
Drug Manufacturers - Specialty & Generic | 3.27% |
|
Shanxi Zhendong Pharmaceutical
SHE:300158 |
Drug Manufacturers - Specialty & Generic | 10.74% |
Annual Asset Resilience Ratio for Hanmi Pharm Co Ltd (2010–2024)
The table below shows the annual Asset Resilience Ratio data for Hanmi Pharm Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.05% | ₩917.66 Million ≈ $621.88K |
₩2.02 Trillion ≈ $1.37 Billion |
-10.50pp |
| 2023-12-31 | 10.54% | ₩200.20 Billion ≈ $135.67 Million |
₩1.90 Trillion ≈ $1.29 Billion |
+5.90pp |
| 2022-12-31 | 4.65% | ₩89.41 Billion ≈ $60.59 Million |
₩1.92 Trillion ≈ $1.30 Billion |
+4.52pp |
| 2021-12-31 | 0.13% | ₩2.51 Billion ≈ $1.70 Million |
₩1.94 Trillion ≈ $1.31 Billion |
+0.03pp |
| 2020-12-31 | 0.10% | ₩1.87 Billion ≈ $1.27 Million |
₩1.88 Trillion ≈ $1.28 Billion |
0.00pp |
| 2019-12-31 | 0.10% | ₩1.98 Billion ≈ $1.34 Million |
₩1.91 Trillion ≈ $1.30 Billion |
-1.75pp |
| 2018-12-31 | 1.85% | ₩31.36 Billion ≈ $21.25 Million |
₩1.69 Trillion ≈ $1.15 Billion |
-3.75pp |
| 2017-12-31 | 5.61% | ₩93.12 Billion ≈ $63.11 Million |
₩1.66 Trillion ≈ $1.13 Billion |
-6.91pp |
| 2016-12-31 | 12.51% | ₩199.83 Billion ≈ $135.42 Million |
₩1.60 Trillion ≈ $1.08 Billion |
+9.95pp |
| 2015-12-31 | 2.57% | ₩44.20 Billion ≈ $29.95 Million |
₩1.72 Trillion ≈ $1.17 Billion |
-1.83pp |
| 2014-12-31 | 4.40% | ₩45.42 Billion ≈ $30.78 Million |
₩1.03 Trillion ≈ $700.28 Million |
-0.19pp |
| 2013-12-31 | 4.59% | ₩40.41 Billion ≈ $27.38 Million |
₩880.87 Billion ≈ $596.95 Million |
+0.75pp |
| 2012-12-31 | 3.84% | ₩32.06 Billion ≈ $21.72 Million |
₩835.59 Billion ≈ $566.27 Million |
+2.60pp |
| 2011-12-31 | 1.24% | ₩9.76 Billion ≈ $6.61 Million |
₩787.75 Billion ≈ $533.85 Million |
+0.72pp |
| 2010-12-31 | 0.52% | ₩3.89 Billion ≈ $2.63 Million |
₩747.72 Billion ≈ $506.72 Million |
-- |
About Hanmi Pharm Co Ltd
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two activ… Read more